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Abstract
Objective—To characterize lifetime and current rates of attention-deficit/hyperactivity disorder 
(ADHD) treatments among US children and adolescents with current ADHD and describe the 
association of these treatments with demographic and clinical factors.
Study design—Data are from the 2014 National Survey of the Diagnosis and Treatment of 
ADHD and Tourette Syndrome, a follow-back survey of parents from the 2011–2012 National 
Survey of Children’s Health. Weighted analyses focused on receipt of ADHD treatment among 
children aged 4–17 years with current ADHD (n = 2495) by 4 treatment types: medication, school 
supports, psychosocial interventions, and alternative treatments.
Results—Medication and school supports were the most common treatments received, with two-
thirds of children and adolescents with ADHD currently receiving each treatment. Social skills 
training was the most common psychosocial treatment ever received (39%), followed by parent 
training (31%), peer intervention (30%), and cognitive behavioral therapy (20%). Among 
alternative treatments, 9% were currently taking dietary supplements, and 11% had ever received 
neurofeedback. Most children (67%) had received at least 2 of the following: current medication 
treatment, current school supports, or lifetime psychosocial treatment; 7% had received none of 
these 3 treatment types.
Conclusions—A majority of school-aged children and adolescents with ADHD received 
medication treatment and school supports, whereas fewer received recommended psychosocial 
interventions. Efforts to increase access to psychosocial treatments may help close gaps in service 
use by groups currently less likely to receive treatment, which is important to ensure that the 
millions of school-aged US children diagnosed with ADHD receive quality treatment.
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Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that 
begins in childhood, results in pervasive functional impairment, and has been diagnosed in 
11% of children aged 4–17 years in the US.1,2 Children with ADHD are more likely than 
their peers to experience adverse long-term outcomes, including poor school outcomes, 
more frequent injury, higher rates of co-occurring psychiatric disorders, and greater 
healthcare utilization.3–6 Treatment guidelines recommend management of patients with 
ADHD according to the chronic care model.7
Medication treatment and parent- and teacher-delivered behavior therapy are evidence-based 
strategies for ADHD treatment; behavior therapy is recommended as the first-line treatment 
for children younger than 6 years, whereas combination therapy (behavior therapy and 
medication treatment) is recommended for children aged 6–11 years and preferred for 
children aged 12 years and older.7–9 A previous study of national parent survey data 
indicated that less than one-half of children with current ADHD (44%) received behavior 
therapy within the past year, whereas 74% received medication in the past week, with 
differences in treatment receipt by demographic factors such as age, race/ethnicity, and 
poverty status.10 However, these data did not allow for estimates by particular type of 
behavioral intervention (eg, peer interventions, parent training, school-based treatments), 
specifically forms that have empirical support as ADHD treatment.8,11–13 Other studies have 
shown trends in psychotherapy use relative to medication usage among children with 
ADHD,14–16 though there is limited published information available regarding specific types 
of psychological treatment received by children and adolescents with ADHD in the 
community.
The purpose of the present study is to characterize lifetime and current rates of 
pharmacologic and nonpharmacologic ADHD treatments overall and by demographic and 
clinical factors among a nationally drawn sample of children and adolescents with ADHD. 
This information can be used to describe the current status of ADHD treatment relative to 
best practices and may inform future research that seeks to identify barriers to receipt of 
recommended treatments as well as policy and programmatic efforts to promote more 
widespread use of recommended treatments for children with ADHD.
Methods
This study used data from the ADHD module of the 2014 National Survey of the Diagnosis 
and Treatment of ADHD and Tourette Syndrome (NS-DATA), a follow-back survey of a 
nationally drawn subgroup of respondent households from the 2011–2012 US National 
Survey of Children’s Health (NSCH). This survey was sponsored by the Centers for Disease 
Control and Prevention’s National Center on Birth Defects and Developmental Disabilities 
and National Center for Health Statistics. A complete description of this survey and sample 
population has been published elsewhere.17,18 Briefly, NS-DATA was a follow-up survey of 
respondent parents and guardians (hereafter referred to as parents) who reported that their 
child had ever received an ADHD diagnosis by a doctor or healthcare provider on the 2011–
2012 NSCH. The response rate for NS-DATA was 47%; when combined with the 23% 
response rate from the 2011–2012 NSCH, the final NS-DATA response rate was 11%. There 
were 2966 completed interviews overall for the ADHD module of NS-DATA; however, the 
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analyses for this study were restricted to the sample of parents with children aged 4–17 years 
who had current ADHD based on parent report at the time of NS-DATA (n = 2495). 
Secondary analysis of these existing deidentified survey data was considered exempt from 
Centers for Disease Control and Prevention institutional review board review.
This study focused on NS-DATA questions related to lifetime and current treatment received 
for ADHD. Specifically, parents were asked whether their child had ever taken medication 
for ADHD, and whether their child had ever received any of the following 7 types of other 
treatments for ADHD or difficulties with their child’s emotions, concentration or behavior: 
(1) “school-based educational support, intervention, or accommodation, such as tutoring, 
extra help from a teacher, preferential seating, extra time to complete work, or being 
enrolled in special education”; (2) “classroom management, such as reward systems, 
behavior modification, or a daily report card”; (3)“peer interventions, such as peer tutoring 
or the Good Behavior Game”19; (4) “social skills training, such as support in how to interact 
with others”; (5) “cognitive behavioral therapy” (CBT); (6) “dietary supplements, herbal 
supplements, or other nonprescription medications” (dietary supplements); or (7) 
“electroencephalogram neurofeedback or other kinds of biofeedback” (neurofeedback). If 
parents reported that their child had ever received any of these treatments or interventions, 
they were asked a follow-up question on whether the child was currently receiving the 
indicated treatment or intervention. Parents were also asked whether they had ever or were 
currently receiving parent training to help manage their child’s ADHD. For this analysis, 
school-based educational support, intervention, or accommodation and classroom 
management were grouped into a single category of school supports, and peer interventions, 
social skills training, CBT, and parent training were grouped into a psychosocial treatment 
category. To compare combinations of treatments, we focused on 3 categories: current 
medication, current school supports, and lifetime receipt of psychosocial treatments. The 
lifetime indicator was used for psychosocial treatments because of longer expected duration 
of effectiveness for these interventions20 compared with the expectation for medication or 
school supports.
Comparisons were made across the following child-level demographic characteristics: sex, 
age (4–11 years, 12–17 years), race (white, black, other), ethnicity (Hispanic/Latino, non-
Hispanic/Latino), primary language in the household (English, other language), household 
poverty status (<100% of federal poverty level, 100%–199% of federal poverty level, ≥200% 
of federal poverty level), health insurance status (private, public, uninsured), continuous 
health insurance during previous 12 months (yes, no), and region of residence (Northeast, 
Midwest, South, West). Additional factors for comparison included current parent-reported 
ADHD severity (mild, moderate, severe), age when the child was first diagnosed with 
ADHD (before 6 years, 6–10 years, 11 years or older), and lifetime or current presence of 
any of the following co-occurring conditions: oppositional defiant disorder, conduct 
disorder, obsessive compulsive disorder, post-traumatic stress disorder, anxiety, bipolar 
disorder, other mood disorder such as depression, autism spectrum disorder or pervasive 
developmental disorder, sleep disorder, intellectual disability, learning disorder, language 
disorder, and tics. Treatment rates were also compared by whether the child had a medical 
home. The medical home indicator used by the National Center on Health Statistics 
incorporates the framework developed by the American Academy of Pediatrics.21 Medical 
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homes are intended to optimize the effectiveness and efficiency of healthcare received by 
children by providing comprehensive and coordinated care. Individual indicators required to 
meet medical home criteria include having a personal physician or nurse, a usual place for 
care when sick, the ability to obtain needed referrals, family-centered care, and effective care 
coordination.22 Most demographic indicators and medical home status were from the 2011–
2012 NSCH; poverty status, insurance status, and all other clinical indicators were collected 
in the 2014 NS-DATA survey.
Subgroup comparisons were tested for statistical significance using χ2 tests. All analyses 
were completed using SAS-callable SUDAAN v 11.0.1 (RTI International, Cary, North 
Carolina) to take into account the complex sample design and sampling weights to adjust for 
selection probability, noncoverage, and nonresponse to minimize potential bias related to 
these factors.
Results
There were survey responses for 2495 children and adolescents with current ADHD reported 
in this survey. The demographic description of the sample can be found in Table I (available 
at www.jpeds.com).
Medication was the most commonly received ADHD treatment, with 90.8% of children in 
this study with current ADHD having ever received medication for ADHD (Figure, Table 
II). The second most common treatment ever received was school supports, with 85.8% of 
children with ADHD having received school accommodations and/or classroom 
management at some point in their lives. Nearly two-thirds of children (62.2%) had ever 
received at least 1 of the 4 psychosocial treatments. Specifically, approximately one-third of 
children with ADHD had ever received social skills training (38.7%), parent training 
(30.9%), or peer intervention (30.2%), whereas 19.8% had ever received CBT. Just under 
one-fifth of children with ADHD had ever received dietary supplements (17.8%) and 
approximately one-tenth had ever received neurofeedback (11.4%).
Approximately two-thirds of children with current ADHD were currently receiving 
medication (66.9%), and a similar percentage (64.7%) were receiving school supports 
(Figure, Table II). About one-third of children with current ADHD were currently receiving 
at least 1 of the psychosocial treatments (32.5%) at the time of the survey; 22.0% were 
receiving social skills training, 12.0% were receiving peer interventions, 10.1% were 
receiving CBT, and 7.9% had parents receiving parent training. Approximately 1 in 10 
children were currently receiving dietary supplements (9.3%), and few children were 
currently receiving neurofeedback (1.5%).
Considering the combination of current medication treatment, current school supports, and 
lifetime psychosocial treatment, one-third of children with ADHD (33.6%) had received all 
three treatments, and another one third (33.2%) had received 2 of the 3. Of the remaining 
treatment combinations, 13.4% were receiving only current medication, 6.7% were receiving 
only current school supports, 6.3% had received only lifetime psychosocial treatment, and 
6.9% had received none of the 3 treatment types.
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Rates of lifetime and current treatments are presented in Table II. Demographic comparisons 
are discussed below using the indicators of current medication and school supports, and 
lifetime services for all psychosocial interventions, with the time frame used for each 
treatment type being selected based on duration of anticipated treatment effectiveness. Rates 
of lifetime psychosocial interventions by type (social skills training, peer interventions, 
CBT, parent training) are presented in Table III.
Treatment rates varied for most demographic groups (Table II and III), though no differences 
were found for treatment rates by child sex or primary language used in the home. Younger 
children (4–11 years of age) were significantly more likely than older children (12–17 years 
of age) to receive each type of treatment with the exception of lifetime parent training (P = .
19) and lifetime peer interventions (P = .08). Treatment rates were generally similar across 
ethnic groups except for current medication treatment, which was more common among 
non-Hispanic children than Hispanic children with ADHD (P = .04). Rates of lifetime peer 
interventions and CBT were significantly associated with race, with the highest rates among 
black children. Increasing poverty was associated with higher lifetime rates of peer 
interventions, social skills training, and parent training. Treatment rates were also strongly 
associated with healthcare coverage type for all treatments except for current medication 
treatment for which differences did not reach statistical significance. For school supports and 
psychosocial treatments, rates were highest among children with public insurance and lowest 
among children without insurance. With the exception of current medication treatment, 
treatment rates were significantly lower among children with a medical home; differences in 
medication rates did not reach statistical significance for children by medical home status. 
Regional differences were detected for receipt of social skills training, with the highest rates 
seen among children with ADHD in the Northeast.
The percentage of children receiving each ADHD treatment increased with parent-reported 
severity of the child’s ADHD (Tables II and III); this association between treatment rates 
and ADHD severity reached statistical significance for all but lifetime peer interventions and 
parent training, for which differences approached statistical significance (.05 ≤ P < .10). Of 
all the subgroups, children with severe ADHD were the most likely to receive medication 
(79.8%) and school supports (78.9%). In fact, these rates were the highest rates of any of the 
demographic or clinical indicator subgroups for any ADHD treatment.
The percentage of children receiving each treatment was significantly associated with age of 
diagnosis (Tables II and III). For all but CBT, there was an inverse relationship between age 
of diagnosis and the percentage receiving each treatment, with children receiving a diagnosis 
at a younger age being more likely to receive each treatment. For CBT, the lowest rate of 
treatment was among those diagnosed from 6 to 10 years of age (14.9%).
Children without a co-occurring disorder were as likely to receive medication treatment as 
children with a current or lifetime report of a co-occurring condition (Tables II and III). 
Children with a co-occurring condition were more likely than children with ADHD alone to 
be receiving school supports and each of the 4 types of psychosocial treatments (peer 
interventions, social skills training, CBT, and parent training).
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Discussion
This study describes patterns of ADHD treatment for children aged 4–17 years with current 
ADHD using a large nationally drawn sample. The results suggest that the 2 most common 
types of ADHD treatments were current medication and school supports, with a minority of 
children with ADHD receiving other recommended treatments (eg, lifetime receipt of peer 
interventions or parents having received parent training) and a small percentage receiving 
alternative treatments such as dietary supplements and neurofeedback. When considering 
combinations of treatment, approximately two-thirds of children were receiving treatment 
from at least 2 categories (current medication, current school supports, or lifetime 
psychosocial treatments), and one-quarter were receiving treatment from only 1 category. 
Approximately 7% were not receiving treatment from any of these 3 categories.
Treatment rates varied independently by child age, race, ethnicity, socioeconomic status, and 
health insurance status but were similar across child sex and primary language in the home. 
Younger children and those who had received the ADHD diagnosis at a younger age were 
generally more likely to receive each type of treatment, suggesting a potential gap in 
services for adolescents and children diagnosed at older ages, particularly for lifetime receipt 
of psychosocial treatment. Similar to prior investigations,23 Hispanic children were less 
likely to receive medication than non-Hispanic children, possibly attributable to cultural 
attitudes toward ADHD medication use. Interestingly, black children and those from families 
with lower socioeconomic status were more likely to have received peer interventions and 
CBT, perhaps as a function of public insurance coverage. Not surprisingly, treatment rates 
were highest for children with severe ADHD, although approximately 20% of children with 
severe symptoms did not currently receive medication or school supports and more than one-
quarter had never received psychosocial treatment. Receipt of care in a medical home was 
associated with lower rates of psychosocial treatment and school supports, potentially 
because of the previously documented inverse relationship of having a medical home and 
severity of condition; children without a medical home were more likely to have severe or 
multiple behavioral health conditions.24 Children with severe ADHD have more complex 
healthcare needs than children with milder ADHD and may benefit more from having 
patient-centered, comprehensive, and coordinated care, yet these are the children with 
ADHD least likely to have a medical home.
The low rates of lifetime behavioral parent training are of particular concern, particularly 
given the recommendation for parent training before medication in children younger than 6 
years of age and the recommendation for combination therapy for older children.7 We have 
previously discussed the barriers to receipt of parent training such as lack of awareness 
about the benefits of behavior training, difficulty in identifying or accessing appropriate 
providers, and the initial cost and time investment needed for behavior training.16 Efforts to 
reduce these barriers and increase family access to parent training could increase the 
opportunity to improve the functional outcomes13 of nearly 1 million school-aged children 
with ADHD whose parents had not received behavioral parent training.
The NS-DATA represents the largest nationally drawn sample specifically of children with 
ADHD collected in the past 2 decades. Given the significant changes in treatment patterns 
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over this time period,2 these unique data provide an opportunity to gain a deeper 
understanding of treatment patterns for the most common neurodevelopmental disorder of 
childhood. However, findings of this study should be taken within the context of several 
considerations. First, the NS-DATA included a predominantly school-aged sample (6–17 
years), with very few 4- to 5-year-olds eligible for this survey. Second, this study followed 
up a cohort of children diagnosed with ADHD at the time of the 2011–2012 NSCH and, 
therefore, had the diagnosis for at least 2–3 years when NS-DATA was conducted. 
Therefore, the sample did not include children who were newly diagnosed and cannot 
describe treatment patterns among those who were recently diagnosed. A related limitation 
is that the follow-up survey did not collect information on all variables of interest, so some 
indicators (eg, having a medical home) were taken from the 2011–2012 NSCH survey and 
may not reflect the child’s current status. Third, this study was intended to provide a 
descriptive characterization of demographic and clinical factors related to treatment of 
ADHD, and the statistics presented do not adjust for these factors when considered together, 
which may limit interpretation of the strength of these associations overall. Fourth, the 
combined overall response rate for NS-DATA was low and may be subject to bias; however, 
the cooperation rate among successfully re-contacted eligible households was high (81%), 
and sampling weights were applied to attempt to mitigate nonresponse bias.17
There are some additional limitations related to the treatment variables specifically. First, the 
data in this study were collected from a single respondent and have not been validated 
against medical or school records. Second, we used the lifetime indicator for psychosocial 
treatments, which may have longer-term effectiveness, but for those not currently receiving 
each treatment, the data do not specify how long since the treatment was last received. Third, 
although this study included a more expansive list of ADHD treatments than previously 
collected in national surveys,2,10 the survey did not include some other treatment types that 
might be commonly used in practice such as play therapy and talk therapy. Finally, there 
may have been some variation in the type, length, quality, and status of the evidence base for 
some of the treatments reported in each question (particularly for school-based supports), 
and as such, this study’s estimates may not reflect the current prevalence of high quality, 
evidence-based treatments received by children with ADHD.
This national profile of ADHD treatment suggests that a majority of school-aged children 
with ADHD receive medication treatment and school services. However, fewer children 
receive recommended psychosocial interventions, including parent behavior training, which 
has the greatest strength of evidence for the treatment of ADHD in children younger than 6 
years.8 Efforts to increase access to psychosocial treatments may help close gaps in service 
use by groups currently less likely to receive treatment, such as adolescents, those diagnosed 
later in childhood, and children without public health insurance. These efforts could include 
training paraprofessionals, using telehealth or mobile technology, or other innovative 
delivery methods. Additional research that further characterizes the types of psychosocial 
treatment and school supports received and how these services vary by children’s 
demographic, insurance, diagnostic, and impairment status as well as reasons why certain 
treatments are less likely to be received by specific subgroups could further inform policy 
efforts to ensure that quality treatment is received by the 5.1 million children and 
adolescents with current ADHD in the US.2
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Glossary
ADHD Attention-deficit/hyperactivity disorder
CBT Cognitive behavioral therapy
NSCH National Survey of Children’s Health
NS-DATA National Survey of the Diagnosis and Treatment of ADHD and Tourette 
Syndrome
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Figure. 
Graph showing percentage of children 4–17 years of age with current ADHD receiving 
treatment, by treatment type (medication, school-based educational support, classroom 
management, social skills training, parent training, peer intervention, cognitive behavioral 
therapy, dietary supplements, and neurofeedback) (NS-DATA 2014).
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Danielson et al. Page 11
Table I
Demographic and clinical characteristics of children with current ADHD (NS-DATA 2014)
Characteristics
Unweighted
N
Weighted
% (95% CI)
Sex*
 Male 1762 70.3 (67.1–73.4)
 Female 733 29.7 (26.6–32.9)
Age group
 4–11 y 768 34.0 (30.7–37.4)
 12–17 y 1727 66.0 (62.6–69.3)
Race*
 White 1940 71.7 (68.3–74.9)
 Black 232 16.2 (13.6–19.1)
 Multiracial/other 312 12.1 (9.9–14.7)
Ethnicity*
 Non-Hispanic/Latino 2276 84.8 (81.7–87.4)
 Hispanic/Latino 213 15.2 (12.6–18.3)
Primary language in the home*
 English 2462 96.7 (94.7–97.9)
 Any other language 32   3.3 (2.1–5.3)
Poverty status
 <100% of federal poverty level 350 28.0 (24.6–31.7)
 100%-199% of federal poverty level 460 22.3 (19.4–25.5)
 ≥200% of federal poverty level 1559 49.7 (46.1–53.2)
Any healthcare coverage
 Public insurance 953 49.7 (46.2–53.2)
 Private insurance 1467 48.6 (45.2–52.1)
 No insurance 37   1.6 (0.9–2.9)
Continuous insurance over past year
 Yes 2316 93.6 (91.5–95.3)
 No 117   6.4 (4.7–8.6)
Receives care in a medical home*
 Yes 1218 43.5 (40.0–46.9)
 No 1208 56.6 (53.1–60.0)
Region*
 Northeast 422 15.3 (13.5–17.3)
 Midwest 592 22.5 (20.5–24.7)
 South 990 44.0 (41.5–46.6)
 West 491 18.2 (16.3–20.2)
Current ADHD severity
 Mild 814 30.3 (27.3–33.5)
 Moderate 1247 49.9 (46.4–53.4)
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Characteristics
Unweighted
N
Weighted
% (95% CI)
 Severe 416 19.9 (17.1–23.0)
Age at diagnosis
 Diagnosed before age 6 y 719 32.2 (29.0–35.6)
 Diagnosed at age 6-10 y 1535 59.6 (56.1–63.0)
 Diagnosed at or after age 11 y 208   8.2 (6.6–10.3)
Ever co-occurring condition†
 None 637 23.9 (21.1–26.9)
 Any 1858 76.1 (73.1–78.9)
Current co-occurring condition†
 None 935 34.3 (31.1–37.6)
 Any 1560 65.7 (62.4–68.9)
*
Indicator collected during 2011-2012 NSCH interview.
†Co-occurring conditions included oppositional defiant disorder, conduct disorder, obsessive compulsive disorder, post-traumatic stress disorder, 
anxiety, bipolar disorder, other mood disorder such as depression, autism spectrum disorder or pervasive developmental disorder, sleep disorder, 
intellectual disability, learning disorder, language disorder, and/or tics.
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ul
tir
ac
ia
l/o
th
er
38
.8
(29
.5–
49
.1)
39
.3
(29
.6–
50
.0)
33
.4
(24
.2–
44
.1)
20
.7
(13
.2–
30
.9)
Et
hn
ic
ity
*
 
N
on
-H
isp
an
ic
/L
at
in
o
38
.6
(35
.1–
42
.2)
29
.9
(26
.7–
33
.4)
30
.0
(26
.6–
33
.6)
19
.6
(16
.7–
22
.8)
 
H
isp
an
ic
/L
at
in
o
39
.9
(30
.1–
50
.6)
36
.8
(27
.3–
47
.4)
30
.6
(21
.5–
41
.4)
19
.8
(12
.6–
29
.6)
Pr
im
ar
y 
la
ng
ua
ge
 in
 th
e 
ho
m
e*
 
En
gl
ish
38
.0
(34
.6–
41
.4)
30
.3
(27
.2–
33
.7)
29
.9
(26
.7–
33
.3)
19
.2
(16
.5–
22
.2)
 
A
ny
 o
th
er
 la
ng
ua
ge
60
.2
(36
.3–
80
.0)
46
.3
(24
.6–
69
.5)
38
.8
†
(18
.9–
63
.4)
39
.5
†
(18
.3–
65
.5)
Pe
rc
en
ta
ge
 o
f f
ed
er
al
 p
ov
er
ty
 le
v
el
 
<
10
0%
47
.5
(39
.7–
55
.4)
41
.4
(33
.8–
49
.3)
42
.8
(35
.2–
50
.7)
25
.0
(18
.6–
32
.7)
 
10
0%
-1
99
%
41
.0
(33
.7–
48
.8)
28
.8
(22
.6–
35
.9)
27
.5
(21
.1–
35
.0)
19
.2
(13
.8–
26
.3)
 
≥2
00
%
32
.1
(28
.2–
36
.4)
26
.7
(23
.0–
30
.8)
23
.9
(20
.1–
28
.2)
17
.7
(14
.4–
21
.5)
A
ny
 h
ea
lth
ca
re
 c
ov
er
ag
e
 
Pu
bl
ic
 in
su
ra
nc
e
47
.5
(42
.2–
52
.9)
35
.9
(30
.9–
41
.2)
38
.9
(33
.7–
44
.3)
25
.0
(20
.5–
30
.2)
 
Pr
iv
at
e 
in
su
ra
nc
e
30
.6
(26
.6–
34
.9)
26
.9
(23
.0–
31
.2)
21
.4
(17
.8–
25
.5)
15
.0
(11
.9–
18
.8)
 
U
ni
ns
ur
ed
15
.6
†
(6.
5–
33
.0)
9.
1‡
(2.
9–
25
.0)
17
.2
†
(7.
2–
35
.8)
11
.6
†
(4.
2–
28
.1)
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So
ci
al
 sk
ill
s t
ra
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g
Pa
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n
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ra
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in
g
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C
og
ni
tiv
e 
be
ha
v
io
ra
l t
he
ra
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%
95
%
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I
%
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%
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I
%
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%
 C
I
%
95
%
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I
Co
nt
in
uo
us
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su
ra
nc
e 
ov
er
 p
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t y
ea
r
 
N
o
29
.3
(18
.2–
43
.5)
29
.6
(17
.7–
45
.2)
24
.0
(13
.9–
38
.4)
14
.0
†
(7.
1–
25
.9)
 
Ye
s
39
.7
(36
.2–
43
.4)
31
.5
(28
.2–
35
.0)
30
.7
(27
.3–
34
.2)
20
.4
(17
.5–
23
.7)
R
ec
ei
v
es
 c
ar
e 
in
 a
 m
ed
ic
al
 h
om
e*
 
N
o
43
.6
(38
.9–
48
.5)
35
.5
(30
.9–
40
.3)
34
.0
(29
.5–
38
.9)
23
.3
(19
.3–
27
.8)
 
Ye
s
31
.2
(26
.7–
36
.2)
26
.1
(21
.9–
30
.9)
24
.9
(20
.6–
29
.9)
15
.3
(11
.8–
19
.7)
R
eg
io
n*
 
N
or
th
ea
st
49
.1
(40
.1–
58
.2)
34
.8
(26
.6–
44
.0)
28
.0
(20
.8–
36
.5)
25
.2
(17
.9–
34
.3)
 
M
id
w
es
t
41
.8
(35
.2–
48
.8)
32
.5
(26
.4–
39
.2)
31
.8
(25
.4–
38
.9)
22
.7
(17
.2–
29
.4)
 
So
ut
h
34
.9
(29
.9–
40
.4)
27
.3
(22
.8–
32
.4)
32
.4
(27
.4–
37
.8)
17
.9
(14
.0–
22
.6)
 
W
es
t
35
.2
(27
.9–
43
.2)
34
.1
(26
.7–
42
.4)
24
.8
(18
.2–
32
.9)
16
.1
(10
.6–
23
.6)
Cu
rre
nt
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D
H
D
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v
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ity
 
M
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26
.2
(21
.2–
32
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26
.5
(21
.5–
32
.1)
27
.1
(21
.7–
33
.3)
13
.9
(9.
9–
19
.1)
 
M
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er
at
e
41
.3
(36
.5–
46
.2)
30
.9
(26
.4–
35
.7)
28
.8
(24
.4–
33
.6)
19
.5
(15
.7–
23
.9)
 
Se
v
er
e
51
.6
(43
.2–
59
.9)
38
.2
(30
.5–
46
.4)
38
.7
(30
.9–
47
.1)
30
.3
(23
.1–
38
.6)
A
ge
 o
f d
ia
gn
os
is
 
B
ef
or
e 
6 
y
53
.7
(47
.3–
60
.0)
38
.4
(32
.4–
44
.7)
38
.6
(32
.5–
45
.0)
28
.6
(23
.0–
34
.9)
 
6–
10
 y
32
.8
(28
.7–
37
.2)
28
.3
(24
.4–
32
.5)
27
.4
(23
.4–
31
.8)
14
.9
(11
.9–
18
.4)
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 o
r o
ld
er
23
.3
(14
.5–
35
.3)
20
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(12
.3–
30
.8)
17
.3
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.9)
23
.0
(13
.8–
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.8)
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o
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u
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§
 
N
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e
15
.1
(10
.9–
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.7)
19
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(14
.1–
25
.1)
16
.4
(11
.8–
22
.4)
3.
6†
(1.
8–
7.1
)
 
A
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46
.2
(42
.2–
50
.2)
34
.6
(30
.9–
38
.5)
34
.6
(30
.8–
38
.7)
25
.0
(21
.6–
28
.8)
Cu
rre
nt
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o-
oc
cu
rri
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di
tio
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N
on
e
18
.2
(14
.4–
22
.9)
19
.5
(15
.4–
24
.3)
17
.2
(13
.2–
22
.2)
6.
6
(4.
4–
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49
.4
(45
.0–
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36
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.1
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26
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 w
as
 s
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 (P
 
<
 .0
5).
U
nd
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† E
st
im
at
e 
is 
un
sta
bl
e 
an
d 
m
ay
 b
e 
un
re
lia
bl
e.
 It
 h
as
 a
 re
la
tiv
e 
st
an
da
rd
 e
rro
r b
et
w
ee
n 
30
%
 a
nd
 5
0%
 an
d 
sh
ou
ld
 b
e i
nt
er
pr
et
ed
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ith
 ca
ut
io
n.
‡ E
st
im
at
e 
is 
un
re
lia
bl
e.
 It
 h
as
 a
 re
la
tiv
e 
st
an
da
rd
 e
rro
r l
ar
ge
r t
ha
n 
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%
 an
d 
sh
ou
ld
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 b
e u
se
d 
ex
ce
pt
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r i
nf
er
en
tia
l s
ta
tis
tic
s (
e.g
., c
om
pa
ris
on
s w
ith
 ot
he
r e
sti
ma
tes
).
§ C
o-
oc
cu
rri
ng
 c
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di
tio
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 in
cl
ud
ed
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pp
os
iti
on
al
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ef
ia
nt
 d
iso
rd
er
,
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n
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 d
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rd
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,
 
o
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es
siv
e 
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m
pu
lsi
v
e 
di
so
rd
er
,
 
po
st-
tra
um
at
ic
 st
re
ss
 d
iso
rd
er
,
 
an
x
ie
ty
,
 
bi
po
la
r d
iso
rd
er
,
 
o
th
er
 m
oo
d 
di
so
rd
er
 su
ch
 a
s 
de
pr
es
sio
n,
 a
ut
ism
 sp
ec
tru
m
 d
iso
rd
er
 o
r p
er
va
siv
e 
de
v
el
op
m
en
ta
l d
iso
rd
er
,
 
sle
ep
 d
iso
rd
er
,
 
in
te
lle
ct
ua
l d
isa
bi
lit
y, 
le
ar
ni
ng
 d
iso
rd
er
,
 
la
ng
ua
ge
 d
iso
rd
er
,
 
an
d/
or
 ti
cs
.
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